NCT07636642 Sixth Generation High-sensitivity Cardiac Troponin T for the Early Rule Out of Myocardial Infarction: a Controlled Before and After Study
| NCT ID | NCT07636642 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Edinburgh |
| Condition | Myocardial Infarction |
| Study Type | INTERVENTIONAL |
| Enrollment | 19,500 participants |
| Start Date | 2026-06-01 |
| Primary Completion | 2028-05 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 19,500 participants in total. It began in 2026-06-01 with a primary completion date of 2028-05.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Cardiac troponin is a protein released into the blood when the heart muscle is damaged. Measuring this protein helps doctors diagnose a heart attack (also called a myocardial infarction). Modern blood tests, known as high-sensitivity cardiac troponin assays, can detect very small amounts of this protein. A new version of this test, called Troponin T high-sensitivity Gen 6, has recently been developed and approved for use. It is designed to be more accurate and reliable, detecting smaller changes in troponin levels and being less affected by technical interference. The investigators believe this improved test will allow doctors to diagnose heart attacks more quickly and decide sooner who needs to stay in hospital and who can safely go home. This could help reduce overcrowding in Accident and Emergency (A\&E) departments, a major challenge for the NHS. This study will examine whether switching to this new test across a health board shortens the time patients with suspected heart attacks spend in the Emergency Department. The investigators will use information from the DataLoch Heart Disease Registry, which automatically collects anonymised hospital data for patients attending with possible heart attacks. The investigators will compare data from one year before and one year after implementation to see whether average length of stay changes and to confirm that patient safety remains high. This investigators will also measure both the current and new versions of the troponin test in surplus blood samples collected during two six-month periods-one before and one after the new test is introduced. This will allows the investigators to directly compare the two tests reliably. Patients will not need to do anything extra to take part - the study uses information and samples already collected as part of their usual care.
Eligibility Criteria
Inclusion Criteria: * Age 18 years and over. * Attending clinician suspects acute coronary syndrome. * At least one measurement of cardiac troponin using the Gen 5 or Gen 6 hs-cTnT assay. Exclusion Criteria: * Insufficient clinical information to perform record linkage. * Not resident in Scotland. * Previous enrolment in the study.
Contact & Investigator
Andrew R Chapman, MD PhD
PRINCIPAL INVESTIGATOR
University of Edinburgh
Frequently Asked Questions
Who can join the NCT07636642 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Myocardial Infarction. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07636642 currently recruiting?
Yes, NCT07636642 is actively recruiting participants. Contact the research team at a.r.chapman@ed.ac.uk for enrollment information.
Where is the NCT07636642 trial being conducted?
This trial is being conducted at Edinburgh, United Kingdom, Edinburgh, United Kingdom, Livingston, United Kingdom.
Who is sponsoring the NCT07636642 clinical trial?
NCT07636642 is sponsored by University of Edinburgh. The principal investigator is Andrew R Chapman, MD PhD at University of Edinburgh. The trial plans to enroll 19,500 participants.